# KHP Ventures

KHP Ventures is a Venture Capital based in London, United Kingdom.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** khpventures.com
- **LinkedIn:** https://www.linkedin.com/company/meridianhealth-ventures

## Regulatory record

- **Reports private funds:** No

## About

The First Transatlantic Health Tech Fund, investing in clinical innovators across Digital Health and MedTech and enabling adoption of transformative solutions at scale. The firm helps ambitious founders and health tech ventures thrive domestically in the UK while fast-tracking their growth in the US. It works with health system partners and portfolio companies to generate real-world data and evidence supporting broader adoption. It invests across two funds: Meridian Health Ventures I and the Innovations in Mental Health Fund.

## Sectors

- Enterprise Software
- AI/ML
- Digital Health
- FinTech

## People

- Dr. Nadine Haram — Co-Managing Partner
- Daniel Dickens — Co-Managing Partner
- Dr. Pooja Sikka — General Partner
- Tim Irish — General Partner
- Dr. Patrik Bächtiger — Venture Partner, Meridian Health Ventures I
- Madhav Mahendra — Principal, Meridian Health Ventures I
- Jing Wei Luo — Head of Legal and Operations
- Dr. Aditi Babel — Associate, Innovations in Mental Health

## Questions

### What is KHP Ventures' relationship with the NHS?

KHP Ventures is backed by King's Health Partners, which integrates King's College London with Guy's and St Thomas' and King's College Hospital NHS Foundation Trusts. This gives the fund direct access to clinical environments, patient populations, and NHS procurement pathways that most independent healthtech VCs cannot replicate without external partnerships. The trusts collectively serve approximately 2.5 million patients annually, creating a substantial pilot environment for portfolio companies.

### How does KHP Ventures source proprietary deal flow?

Deal flow is sourced primarily through the clinical and research networks of King's Health Partners. Clinicians and academics identify workflow inefficiencies and emerging technologies with direct applicability inside the NHS, giving the fund early visibility into startups that align with real operational needs. This clinical-first sourcing model means portfolio companies are evaluated on utility inside a large teaching hospital system before market-fit analysis common at generalist funds.

### What investment stages does KHP Ventures target?

The firm focuses on pre-seed and seed-stage investments, entering at the earliest point where clinical validation and an NHS pilot can materially de-risk the technology. This stage preference reflects the structural advantage of the fund: bringing portfolio companies into live clinical settings for iterative co-development with frontline practitioners before broader commercial rollout.

### Does KHP Ventures participate in fund commitments or only direct deals?

The firm's known posture is direct early-stage investing rather than fund-of-funds commitments. This aligns with its structural design: the value proposition to limited partners and portfolio companies rests on direct clinical access, which is meaningful at the company level but dilutes in a fund-of-funds model. No public record identifies fund commitment activity.

## Related profiles

- [Khosla Impact](https://altss.com/profile/khosla-impact)
- [Khulasande Capital](https://altss.com/profile/khulasande-capital)

---

Last updated: 2026-08-11T15:07:12.582Z

Canonical page: https://altss.com/profile/khp-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology